바이오스펙테이터

바이오스펙테이터 Sungmin Kim 기자

“Anterogen’s ultimate targeting market is a rare disease market in Japan, America, and Europe. Anterogen has strategized to achieve a top with excellently effective therapeutics in rare disease market in which having no reasonable treatment alternatives. It is not aiming at a large-scale market but a niche market where there is no competitor. The rare disease market is growing and increasing its sales in worldwide.”

This difference is what the representative of Anterogen, Lee Sung Koo, has: different target market from other companies. It is interesting to view Anterogen’s recent movement that reflects exactly what he meant. Anterogen had recently signed a contract with Ishin pharmaceuticals in Japan, with a total of 90 billion won down payment and milestone. Anterogen just received a total payment of 3.8 billion won solely as licensing fee regarding the technology, and has entered into the clinical stage in Japan. In addition, two other IND were approved from the U.S. Food and Drug Administration (FDA) with the same therapeutics.

This therapeutic product, which is accelerating into the global market, is the ‘ALLO-ASC-Sheet’ for rare skin diseases: a patch preparation using mesenchymal stem cells. Its beginning was in an effort to overcome the limitations of conventional stem cell therapy. Compared to the reputation of ‘stem cells’, stem cell therapy had continuously failed in clinical trials due to limited efficacy and its uniformed product manufacturing. So far, there are only seven cases of treatment that had been approved globally. And this can be interpreted in the same context. Stem cell therapies have been in the market for a while but were not getting spotlights because of its complicate procedures and expensive price from the reason of personalized medicine characteristics, almost impossible logistics.

관련기사

• 안트로젠 "국산 줄기세포 치료제로 美∙日희귀질환시장 진출"